|
1
|
Ferlay J, Colombet M, Soerjomataram I,
Parkin DM, Pineros M, Znaor A and Bray F: Cancer statistics for the
year 2020: An overview. Int J Cancer. Apr 5–2021.Epub ahead of
print. View Article : Google Scholar
|
|
2
|
Xia YX, Zhang F, Li XC, Kong LB, Zhang H,
Li DH, Cheng F, Pu LY, Zhang CY, Qian XF, et al: Surgical treatment
of primary liver cancer:A report of 10 966 cases. Zhonghua Wai Ke
Za Zhi. 59:6–17. 2021.In Chinese.
|
|
3
|
Cordova-Bahena L and Velasco-Velazquez MA:
Anti-PD-1 And Anti-PD-L1 antibodies as immunotherapy against
cancer: A structural perspective. Rev Invest Clin. 73:008–016.
2020.
|
|
4
|
Kuol N, Stojanovska L, Nurgali K and
Apostolopoulos V: PD-1/PD-L1 in disease. Immunotherapy. 10:149–160.
2018. View Article : Google Scholar
|
|
5
|
Emens LA: Breast cancer immunotherapy:
Facts and hopes. Clin Cancer Res. 24:511–520. 2018. View Article : Google Scholar
|
|
6
|
Sengupta R and Honey K: AACR cancer
progress report 2019: Transforming lives through innovative cancer
science. Clin Cancer Res. 25:54312019. View Article : Google Scholar
|
|
7
|
Xin Yu J, Hubbard-Lucey VM and Tang J:
Immuno-oncology drug development goes global. Nat Rev Drug Discov.
18:899–900. 2019. View Article : Google Scholar
|
|
8
|
Ho YJ, Li JP, Fan CH, Liu HL and Yeh CK:
Ultrasound in tumor immunotherapy: Current status and future
developments. J Control Release. 323:12–23. 2020. View Article : Google Scholar
|
|
9
|
Keir ME, Butte MJ, Freeman GJ and Sharpe
AH: PD-1 and its ligands in tolerance and immunity. Annu Rev
Immunol. 26:677–704. 2008. View Article : Google Scholar
|
|
10
|
Patel SP and Kurzrock R: PD-L1 expression
as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther.
14:847–856. 2015. View Article : Google Scholar
|
|
11
|
Kythreotou A, Siddique A, Mauri FA, Bower
M and Pinato DJ: Pd-L1. J Clin Pathol. 71:189–194. 2018. View Article : Google Scholar
|
|
12
|
Ghosh C, Luong G and Sun Y: A snapshot of
the PD-1/PD-L1 pathway. J Cancer. 12:2735–2746. 2021. View Article : Google Scholar
|
|
13
|
Ai L, Xu A and Xu J: Roles of PD-1/PD-L1
pathway: Signaling, cancer, and beyond. Adv Exp Med Biol.
1248:33–59. 2020. View Article : Google Scholar
|
|
14
|
Jiang Y, Chen M, Nie H and Yuan Y: PD-1
and PD-L1 in cancer immunotherapy: Clinical implications and future
considerations. Hum Vaccin Immunother. 15:1111–1122. 2019.
View Article : Google Scholar
|
|
15
|
Meng X, Liu X, Guo X, Jiang S, Chen T, Hu
Z, Liu H, Bai Y, Xue M, Hu R, et al: FBXO38 mediates PD-1
ubiquitination and regulates anti-tumour immunity of T cells.
Nature. 564:130–135. 2018. View Article : Google Scholar
|
|
16
|
Burr ML, Sparbier CE, Chan YC, Williamson
JC, Woods K, Beavis PA, Lam EYN, Henderson MA, Bell CC, Stolzenburg
S, et al: CMTM6 maintains the expression of PD-L1 and regulates
anti-tumour immunity. Nature. 549:101–105. 2017. View Article : Google Scholar
|
|
17
|
Mezzadra R, Sun C, Jae LT, Gomez-Eerland
R, de Vries E, Wu W, Logtenberg MEW, Slagter M, Rozeman EA, Hofland
I, et al: Identification of CMTM6 and CMTM4 as PD-L1 protein
regula-tors. Nature. 549:106–110. 2017. View Article : Google Scholar
|
|
18
|
Baumeister SH, Freeman GJ, Dranoff G and
Sharpe AH: Coinhibitory Pathways in Immunotherapy for Cancer. Annu
Rev Immunol. 34:539–573. 2016. View Article : Google Scholar
|
|
19
|
Burugu S, Dancsok AR and Nielsen TO:
Emerging targets in cancer immunotherapy. Semin Cancer Biol.
52:39–52. 2018. View Article : Google Scholar
|
|
20
|
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux
M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al: Atezolizumab
plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J
Med. 382:1894–1905. 2020. View Article : Google Scholar
|
|
21
|
Forde PM, Chaft JE and Pardoll DM:
Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med.
379:e142018. View Article : Google Scholar
|
|
22
|
Zhu XD, Huang C, Shen YH, Ji Y, Ge NL, Qu
XD, Chen L, Shi WK, Li ML, Zhu JJ, et al: Downstaging and resection
of initially unresectable hepatocellular carcinoma with tyrosine
kinase inhibitor and anti-PD-1 antibody combinations. Liver Cancer.
10:320–329. 2021. View Article : Google Scholar
|
|
23
|
Xu ZN, Huang JJ, Zhou J, Huang WS, Guo YJ,
Cai MY, Zhou JW, Lin LT, Liang LC and Zhu KS: Efficacy and safety
of anti-PD-1 monoclonal antibody in advanced hepatocellular
carcinoma after TACE combined with TKI therapy. Zhonghua Nei Ke Za
Zhi. 60:630–636. 2021.In Chinese.
|
|
24
|
Xie D, Sun Q, Wang X, Zhou J, Fan J, Ren Z
and Gao Q: Immune checkpoint inhibitor plus tyrosine kinase
inhibitor for unresectable hepatocellular carcinoma in the real
world. Ann Transl Med. 9:6522021. View Article : Google Scholar
|
|
25
|
Xu J, Shen J, Gu S, Zhang Y, Wu L, Wu J,
Shao G, Zhang Y, Xu L, Yin T, et al: Camrelizumab in combination
with apatinib in patients with advanced hepatocellular carcinoma
(RESCUE): A nonrandomized, open-label, phase II trial. Clin Cancer
Res. 27:1003–1011. 2021. View Article : Google Scholar
|
|
26
|
Hussaini S, Chehade R, Boldt RG, Raphael
J, Blanchette P, Maleki Vareki S and Fernandes R: Association
between immune-related side effects and efficacy and benefit of
immune checkpoint inhibitors-A systematic review and meta-analysis.
Cancer Treat Rev. 92:1021342021. View Article : Google Scholar
|
|
27
|
Heinzerling L, de Toni EN, Schett G,
Hundorfean G and Zimmer L: Checkpoint Inhibitors. Dtsch Arztebl
Int. 116:119–126. 2019.
|
|
28
|
Martins F, Sofiya L, Sykiotis GP, Lamine
F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A,
Guex-Crosier Y, et al: Adverse effects of immune-checkpoint
inhibitors: Epidemiology, management and surveillance. Nat Rev Clin
Oncol. 16:563–580. 2019. View Article : Google Scholar
|
|
29
|
Zimmer L, Goldinger SM, Hofmann L, Loquai
C, Ugurel S, Thomas I, Schmidgen MI, Gutzmer R, Utikal JS, Goppner
D, et al: Neurological, respiratory, musculoskeletal, cardiac and
ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 60:210–225.
2016. View Article : Google Scholar
|
|
30
|
Liao B, Shroff S, Kamiya-Matsuoka C and
Tummala S: Atypical neurological complications of ipilimumab
therapy in patients with metastatic melanoma. Neuro Oncol.
16:589–593. 2014. View Article : Google Scholar
|
|
31
|
Voskens CJ, Goldinger SM, Loquai C, Robert
C, Kaehler KC, Berking C, Bergmann T, Bockmeyer CL, Eigentler T,
Fluck M, et al: The price of tumor control: An analysis of rare
side effects of anti-CTLA-4 therapy in metastatic melanoma from the
ipilimumab network. PLoS One. 8:e537452013. View Article : Google Scholar
|
|
32
|
Wilgenhof S and Neyns B: Anti-CTLA-4
antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann
Oncol. 22:991–993. 2011. View Article : Google Scholar
|
|
33
|
Bot I, Blank CU, Boogerd W and Brandsma D:
Neurological immune-related adverse events of ipilimumab. Pract
Neurol. 13:278–280. 2013. View Article : Google Scholar
|
|
34
|
De Giorgio R, Guerrini S, Barbara G,
Stanghellini V, De Ponti F, Corinaldesi R, Moses PL, Sharkey KA and
Mawe GM: Inflammatory neuropathies of the enteric nervous system.
Gastroenterology. 126:1872–1883. 2004. View Article : Google Scholar
|
|
35
|
Liu WK, Naban N, Kaul A, Patel N and Fusi
A: Life-threatening polymyositis with spontaneous hematoma induced
by nivolumab in a patient with previously resected melanoma.
Melanoma Res. 31:85–87. 2021. View Article : Google Scholar
|
|
36
|
Makarious D, Horwood K and Coward JIG:
Myasthenia gravis: An emerging toxicity of immune checkpoint
inhibitors. Eur J Cancer. 82:128–136. 2017. View Article : Google Scholar
|
|
37
|
Hayakawa N, Kikuchi E, Suzuki S and Oya M:
Myasthenia gravis with myositis induced by pembrolizumab therapy in
a patient with metastatic urothelial carcinoma. Int Cancer Conf J.
9:123–126. 2020. View Article : Google Scholar
|
|
38
|
Safa H, Johnson DH, Trinh VA, Rodgers TE,
Lin H, Suarez-Almazor ME, Fa'ak F, Saberian C, Yee C, Davies MA, et
al: Immune checkpoint inhibitor related myasthenia gravis: Single
center experience and systematic review of the literature. J
Immunother Cancer. 7:3192019. View Article : Google Scholar
|
|
39
|
Pottier C, El Habnouni C, Kervarrec T,
Beltran S and Samimi M: Myasthenia gravis induced by pembrolizumab
in a patient with metastatic Merkel cell carcinoma. Ann Dermatol
Venereol. Feb 18–2022.Epub ahead of print. View Article : Google Scholar
|
|
40
|
Tian CY, Ou YH, Chang SL and Lin CM:
Pembrolizumab-induced myasthenia gravis-like disorder, ocular
myositis, and hepatitis: A case report. J Med Case Rep. 15:2442021.
View Article : Google Scholar
|
|
41
|
Heleno CT, Mustafa A, Gotera NA and Tesar
A: Myasthenia gravis as an immune-mediated side effect of
checkpoint inhibitors. Cureus. 13:e163162021.
|
|
42
|
Vogel WV, Guislain A, Kvistborg P,
Schumacher TN, Haanen JB and Blank CU: Ipilimumab-induced
sarcoidosis in a patient with metastatic melanoma undergoing
complete remission. J Clin Oncol. 30:e7–e10. 2012. View Article : Google Scholar
|
|
43
|
Eckert A, Schoeffler A, Dalle S, Phan A,
Kiakouama L and Thomas L: Anti-CTLA4 monoclonal antibody induced
sarcoidosis in a metastatic melanoma patient. Dermatology.
218:69–70. 2009. View Article : Google Scholar
|
|
44
|
Wilgenhof S, Morlion V, Seghers AC, Du
Four S, Vanderlinden E, Hanon S, Vandenbroucke F, Everaert H and
Neyns B: Sarcoidosis in a patient with metastatic melanoma
sequentially treated with anti-CTLA-4 monoclonal antibody and
selective BRAF inhibitor. Anticancer Res. 32:1355–1359. 2012.
|
|
45
|
Mandel JJ, Olar A, Aldape KD and
Tremont-Lukats IW: Lambrolizumab induced central nervous system
(CNS) toxicity. J Neurol Sci. 344:229–231. 2014. View Article : Google Scholar
|
|
46
|
Barjaktarevic IZ, Qadir N, Suri A,
Santamauro JT and Stover D: Organizing pneumonia as a side effect
of ipilimumab treatment of melanoma. Chest. 143:858–861. 2013.
View Article : Google Scholar
|
|
47
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar
|
|
48
|
Rizvi NA, Mazieres J, Planchard D,
Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E,
Mennecier B, et al: Activity and safety of nivolumab, an anti-PD-1
immune check-point inhibitor, for patients with advanced,
refractory squamous non-small-cell lung cancer (CheckMate 063): A
phase 2, single-arm trial. Lancet Oncol. 16:257–265. 2015.
View Article : Google Scholar
|
|
49
|
Topalian SL, Sznol M, McDermott DF, Kluger
HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB,
Powderly JD, et al: Survival, durable tumor remission, and
long-term safety in patients with advanced melanoma receiving
nivolumab. J Clin Oncol. 32:1020–1030. 2014. View Article : Google Scholar
|
|
50
|
Yu H, Li J, Yu L, Cheng X, Han X and Zhang
X: A case report of checkpoint inhibitor pneumonitis caused by
PD-1Antibody-safety and effectiveness of pirfenidone. Zhongguo Fei
Ai Za Zhi. 24:519–525. 2021.In Chinese.
|
|
51
|
Donato AA and Krol R: Allergic
bronchopulmonary aspergillosis presumably unmasked by PD-1
inhibition. BMJ Case Rep. 12:e2278142019. View Article : Google Scholar
|
|
52
|
Fragkou P, Souli M, Theochari M,
Kontopoulou C, Loukides S and Koumarianou A: A case of organizing
pneumonia (OP) associated with pembrolizumab. Drug Target Insights.
10:9–12. 2016. View Article : Google Scholar
|
|
53
|
Vartanov A, Kalotra A, Varughese J, Gautam
S, Kandel S and Hosmer W: Immunotherapy-associated complete heart
block in a patient with NSCLC: A case report and literature review.
Respir Med Case Rep. 33:1013902021.
|
|
54
|
Läubli H, Balmelli C, Bossard M, Pfister
O, Glatz K and Zippelius A: Acute heart failure due to autoimmune
myocarditis under pembrolizumab treatment for metastatic melanoma.
J Immunother Cancer. 3:112015. View Article : Google Scholar
|
|
55
|
Bukamur HS, Mezughi H, Karem E, Shahoub I
and Shweihat Y: Nivolumab-induced third degree atrioventricular
block in a patient with stage IV squamous cell lung carcinoma.
Cureus. 11:e48692019.
|
|
56
|
Cousin S, Seneschal J and Italiano A:
Toxicity profiles of immunotherapy. Pharmacol Ther. 181:91–100.
2018. View Article : Google Scholar
|
|
57
|
Puzanov I, Diab A, Abdallah K, Bingham CO
III, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR,
et al: Managing toxicities associated with immune checkpoint
inhibitors: Consensus recommendations from the Society for
Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J
Immunother Cancer. 5:952017. View Article : Google Scholar
|
|
58
|
Tso DK, Avery LL, Lev MH and Kamalian S:
Nivolumab-induced small bowel obstruction and perforation: A rare
but life-threatening side effect of immunotherapy. Emerg Radiol.
27:107–110. 2020. View Article : Google Scholar
|
|
59
|
Mathew Thomas V, Bindal P, Ann Alexander S
and McDonald K: Nivolumab-induced hepatitis: A rare side effect of
an immune check point inhibitor. J Oncol Pharm Pract. 26:459–461.
2020. View Article : Google Scholar
|
|
60
|
Lankes K, Hundorfean G, Harrer T, Pommer
AJ, Agaimy A, Angelovska I, Tajmir-Riahi A, Gohl J, Schuler G,
Neurath MF, et al: Anti-TNF-refractory colitis after checkpoint
inhibitor therapy: Possible role of CMV-mediated
immunopathogenesis. Oncoimmunology. 5:e11286112016. View Article : Google Scholar
|
|
61
|
Kichloo A, Albosta MS, McMahon S,
Movsesian K, Wani F, Jamal SM, Aljadah M and Singh J:
Pembrolizumab-induced diabetes mellitus presenting as diabetic
ketoacidosis in a patient with metastatic colonic adenocarcinoma. J
Investig Med High Impact Case Rep. 8:23247096209513392020.
|
|
62
|
Villadolid J and Amin A: Immune checkpoint
inhibitors in clinical practice: Update on management of
immune-related toxicities. Transl Lung Cancer Res. 4:560–575.
2015.
|
|
63
|
Belum VR, Benhuri B, Postow MA, Hellmann
MD, Lesokhin AM, Segal NH, Motzer RJ, Wu S, Busam KJ, Wolchok JD
and Lacouture ME: Characterisation and management of dermatologic
adverse events to agents targeting the PD-1 receptor. Eur J Cancer.
60:12–25. 2016. View Article : Google Scholar
|
|
64
|
Naidoo J, Page DB, Li BT, Connell LC,
Schindler K, Lacouture ME, Postow MA and Wolchok JD: Toxicities of
the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann
Oncol. 27:13622016. View Article : Google Scholar
|
|
65
|
Mullangi S, Ponnam S, Lekkala MR and Koya
S: A case of de novo psoriasis secondary to nivolumab in a patient
with meta-static renal cell carcinoma. Cureus. 13:e157032021.
|
|
66
|
Acar A, Oraloglu G, Yaman B and Karaarslan
I: Nivolumab-induced plaque morphea in a malign melanoma patient. J
Cosmet Dermatol. 20:2645–2647. 2021. View Article : Google Scholar
|
|
67
|
Mobini N, Dhillon R, Dickey J, Spoon J and
Sadrolashrafi K: Exclusive cutaneous and subcutaneous sarcoidal
granulomatous inflammation due to immune checkpoint inhibitors:
Report of two cases with unusual manifestations and review of the
literature. Case Rep Dermatol Med. 2019:67028702019.
|
|
68
|
De Bock M, Hulstaert E, Kruse V and
Brochez L: Psoriasis vulgaris exacerbation during treatment with a
PD-1 check-point inhibitor: Case report and literature review. Case
Rep Dermatol. 10:190–197. 2018. View Article : Google Scholar
|
|
69
|
Izzedine H, Gueutin V, Gharbi C, Mateus C,
Robert C, Routier E, Thomas M, Baumelou A and Rouvier P: Kidney
injuries related to ipilimumab. Invest New Drugs. 32:769–773. 2014.
View Article : Google Scholar
|
|
70
|
Lefebvre J and Glezerman IG: Kidney
toxicities associated with novel cancer therapies. Adv Chronic
Kidney Dis. 24:233–240. 2017. View Article : Google Scholar
|
|
71
|
Schneider S, Alezra E, Yacoub M, Ducharme
O, Gerard E, Dutriaux C and Prey S: Aseptic cystitis induced by
nivolumab and ipilimumab combination for metastatic melanoma.
Melanoma Res. 31:487–489. 2021. View Article : Google Scholar
|
|
72
|
Thummalapalli R, Melms JC, Mier J and Izar
B: Rapid evolution of acute kidney injury after initial infusion of
pembrolizumab in a melanoma patient concurrently treated with
RAF/MEK inhibitors. Melanoma Res. 30:219–222. 2020. View Article : Google Scholar
|
|
73
|
Uchida A, Watanabe M, Nawata A, Ikari Y,
Sasaki M, Shigemoto K, Hisano S and Nakashima H: Tubulointerstitial
nephritis as adverse effect of programmed cell death 1 inhibitor,
nivolumab, showed distinct histological findings. CEN Case Rep.
6:169–174. 2017. View Article : Google Scholar
|
|
74
|
Atwal D, Joshi KP, Ravilla R and Mahmoud
F: Pembrolizumab-induced pancytopenia: A case report. Perm J.
21:17–004. 2017.
|
|
75
|
Michot JM, Vargaftig J, Leduc C, Quere G,
Burroni B, Lazarovici J, Champiat S, Ribrag V and Lambotte O:
Immune-related bone marrow failure following anti-PD1 therapy. Eur
J Cancer. 80:1–4. 2017. View Article : Google Scholar
|
|
76
|
Comito RR, Badu LA and Forcello N:
Nivolumab-induced aplastic anemia: A case report and literature
review. J Oncol Pharm Pract. 25:221–225. 2019. View Article : Google Scholar
|
|
77
|
Jotatsu T, Oda K, Yamaguchi Y, Noguchi S,
Kawanami T, Kido T, Satoh M and Yatera K: Immune-mediated
thrombocytopenia and hypothyroidism in a lung cancer patient
treated with nivolumab. Immunotherapy. 10:85–91. 2018. View Article : Google Scholar
|
|
78
|
Kumar V, Chaudhary N, Garg M, Floudas CS,
Soni P and Chandra AB: Corrigendum: Current diagnosis and
management of immune related adverse events (irAEs) induced by
immune checkpoint inhibitor therapy. Front Pharmacol.
8:3112017.
|
|
79
|
Obata S, Saishin Y, Teramura K and Ohji M:
Vogt-koyanagiharada disease-like uveitis during nivolumab
(Anti-PD-1 Antibody) treatment for metastatic cutaneous malignant
melanoma. Case Rep Ophthalmol. 10:67–74. 2019. View Article : Google Scholar
|
|
80
|
Theillac C, Straub M, Breton AL, Thomas L
and Dalle S: Bilateral uveitis and macular edema induced by
Nivolumab: A case report. BMC Ophthalmol. 17:2272017. View Article : Google Scholar
|
|
81
|
Lidar M, Giat E, Garelick D, Horowitz Y,
Amital H, Steinberg-Silman Y, Schachter J, Shapira-Frommer R and
Markel G: Rheumatic manifestations among cancer patients treated
with immune checkpoint inhibitors. Autoimmun Rev. 17:284–289. 2018.
View Article : Google Scholar
|
|
82
|
Spain L, Diem S and Larkin J: Management
of toxicities of immune checkpoint inhibitors. Cancer Treat Rev.
44:51–60. 2016. View Article : Google Scholar
|
|
83
|
Cappelli LC, Gutierrez AK, Baer AN,
Albayda J, Manno RL, Haque U, Lipson EJ, Bleich KB, Shah AA, Naidoo
J, et al: Inflammatory arthritis and sicca syndrome induced by
nivolumab and ipilimumab. Ann Rheum Dis. 76:43–50. 2017. View Article : Google Scholar
|
|
84
|
Belkhir R, Burel SL, Dunogeant L,
Marabelle A, Hollebecque A, Besse B, Leary A, Voisin AL, Pontoizeau
C, Coutte L, et al: Rheumatoid arthritis and polymyalgia rheumatica
occurring after immune checkpoint inhibitor treatment. Ann Rheum
Dis. 76:1747–1750. 2017. View Article : Google Scholar
|
|
85
|
Almutairi AR, McBride A, Slack M, Erstad
BL and Abraham I: Potential immune-related adverse events
associated with mono-therapy and combination therapy of ipilimumab,
nivolumab, and pembrolizumab for advanced melanoma: A systematic
review and meta-analysis. Front Oncol. 10:912020. View Article : Google Scholar
|
|
86
|
Xu C, Chen YP, Du XJ, Liu JQ, Huang CL,
Chen L, Zhou GQ, Li WF, Mao YP, Hsu C, et al: Comparative safety of
immune checkpoint inhibitors in cancer: Systematic review and
network meta-analysis. BMJ. 363:k42262018. View Article : Google Scholar
|
|
87
|
Lee J, Graham A and Sion A: Evaluation of
arthralgias in adult oncology patients receiving immune checkpoint
inhibitors. J Oncol Pharm Pract. 25:1867–1872. 2019. View Article : Google Scholar
|
|
88
|
Buder-Bakhaya K, Benesova K, Schulz C,
Anwar H, Dimitrakopoulou-Strauss A, Weber TF, Enk A, Lorenz HM and
Hassel JC: Characterization of arthralgia induced by PD-1 antibody
treatment in patients with metastasized cutaneous malignancies.
Cancer Immunol Immunother. 67:175–182. 2018. View Article : Google Scholar
|
|
89
|
Al-Dliw M, Megri M, Shahoub I, Sahay G,
Limjoco TI and Shweihat Y: Pembrolizumab reactivates pulmonary
granulomatosis. Respir Med Case Rep. 22:126–129. 2017.
|
|
90
|
Noguchi S, Kawachi H, Yoshida H, Fukao A,
Terashita S, Ikeue T, Horikawa S and Sugita T: Sarcoid-Like
granulomatosis induced by nivolumab treatment in a lung cancer
patient. Case Rep Oncol. 11:562–566. 2018. View Article : Google Scholar
|
|
91
|
Nikolakis G, Brunner M, Boye H, Arndt N,
Altenburg A, Vaiopoulos A and Zouboulis CC: Enlarged mediastinal
lymph nodes of a patient with malignant melanoma stage IV under
pembrolizumab treatment. Hautarzt. 70:443–446. 2019.In German.
View Article : Google Scholar
|
|
92
|
Lederhandler MH, Ho A, Brinster N, Ho RS,
Liebman TN and Lo Sicco K: Severe oral mucositis: A rare adverse
event of pembrolizumab. J Drugs Dermatol. 17:807–809. 2018.
|
|
93
|
Parakh S, Cebon J and Klein O: Delayed
autoimmune toxicity occurring several months after cessation of
anti-PD-1 therapy. Oncologist. 23:849–851. 2018. View Article : Google Scholar
|
|
94
|
Moreira A, Loquai C, Pfohler C, Kahler KC,
Knauss S, Heppt MV, Gutzmer R, Dimitriou F, Meier F, Mitzel-Rink H,
et al: Myositis and neuromuscular side-effects induced by immune
checkpoint inhibitors. Eur J Cancer. 106:12–23. 2019. View Article : Google Scholar
|
|
95
|
Neilan TG, Rothenberg ML, Amiri-Kordestani
L, Sullivan RJ, Steingart RM, Gregory W, Hariharan S, Hammad TA,
Lindenfeld J, Murphy MJ, et al: Myocarditis associated with immune
checkpoint inhibitors: An expert consensus on data Gaps and a call
to action. Oncologist. 23:874–878. 2018. View Article : Google Scholar
|
|
96
|
Alnabulsi R, Hussain A and DeAngelis D:
Complete ophthal-moplegia in Ipilmumab and Nivolumab combination
treatment for metastatic melanoma. Orbit. 37:381–384. 2018.
View Article : Google Scholar
|
|
97
|
Kurokawa M, Kurokawa R, Hagiwara A, Gonoi
W, Harayama S, Koizumi K, Yoshino K, Hishima T, Baba A, Ota Y, et
al: CT imaging findings of anti-PD-1 inhibitor-related
enterocolitis. Abdom Radiol (NY). 46:3033–3043. 2021. View Article : Google Scholar
|
|
98
|
Luoma AM, Suo S, Williams HL, Sharova T,
Sullivan K, Manos M, Bowling P, Hodi FS, Rahma O, Sullivan RJ, et
al: Molecular pathways of colon inflammation induced by cancer
immunotherapy. Cell. 182:655–671.e22. 2020. View Article : Google Scholar
|
|
99
|
Zhao L, Yu J, Wang J, Li H, Che J and Cao
B: Risk of immune-related diarrhea with PD-1/PD-L1 inhibitors in
different cancer types and treatment regimens. J Cancer. 11:41–50.
2020. View Article : Google Scholar
|
|
100
|
Shivaji UN, Jeffery L, Gui X, Smith SCL,
Ahmad OF, Akbar A, Ghosh S and Iacucci M: Immune checkpoint
inhibitor-associated gastrointestinal and hepatic adverse events
and their manage-ment. Therap Adv Gastroenterol. Nov 5–2019.Epub
ahead of print. View Article : Google Scholar
|
|
101
|
Alvarez M, Otano I, Minute L, Ochoa MC,
Perez-Ruiz E, Melero I and Berraondo P: Impact of prophylactic TNF
blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and
toxicity. Cell Stress. 3:236–239. 2019. View Article : Google Scholar
|
|
102
|
Nadeau BA, Fecher LA, Owens SR and
Razumilava N: Liver toxicity with cancer checkpoint inhibitor
therapy. Semin Liver Dis. 38:366–378. 2018. View Article : Google Scholar
|
|
103
|
Straub BK, Ridder DA, Schad A, Loquai C
and Schattenberg JM: Liver injury induced by immune checkpoint
inhibitor-therapy: Example of an immune-mediated drug side effect.
Pathologe. 39:556–562. 2018.In German. View Article : Google Scholar
|
|
104
|
Rahman W, Conley A and Silver KD:
Atezolizumab-induced type 1 diabetes mellitus in a patient with
metastatic renal cell carcinoma. BMJ Case Rep. 13:e2338422020.
View Article : Google Scholar
|
|
105
|
Quandt Z, Young A and Anderson M: Immune
checkpoint inhibitor diabetes mellitus: A novel form of autoimmune
diabetes. Clin Exp Immunol. 200:131–140. 2020. View Article : Google Scholar
|
|
106
|
Agrawal L, Bacal A, Jain S, Singh V,
Emanuele N, Emanuele M and Meah F: Immune checkpoint inhibitors and
endocrine side effects, a narrative review. Postgrad Med.
132:206–214. 2020. View Article : Google Scholar
|
|
107
|
Bailly C: Potential use of edaravone to
reduce specific side effects of chemo-, radio-and immuno-therapy of
cancers. Int Immunopharmacol. 77:1059672019. View Article : Google Scholar
|
|
108
|
Zhu Y, Wu HH and Wang W: A case of
small-cell lung cancer with adrenocorticotropic hormone deficiency
induced by nivolumab. Onco Targets Ther. 12:2181–2186. 2019.
View Article : Google Scholar
|
|
109
|
Li S, Zhang Y, Sun Z, Hu J and Fang C:
Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese
patient: A case report. Medicine (Baltimore). 97:e129072018.
View Article : Google Scholar
|
|
110
|
Solinas C, Porcu M, De Silva P, Musi M,
Aspeslagh S, Scartozzi M, Willard-Gallo K, Mariotti S and Saba L:
Cancer immunotherapy-associated hypophysitis. Semin Oncol.
45:181–186. 2018. View Article : Google Scholar
|
|
111
|
Briet C, Albarel F, Kuhn E, Merlen E,
Chanson P and Cortet C: Expert opinion on pituitary complications
in immunotherapy. Ann Endocrinol (Paris). 79:562–568. 2018.
View Article : Google Scholar
|
|
112
|
Clotman K, Janssens K, Specenier P, Weets
I and De Block CEM: Programmed cell death-1 inhibitor-induced type
1 diabetes mellitus. J Clin Endocrinol Metab. 103:3144–3154. 2018.
View Article : Google Scholar
|
|
113
|
Sagiv O, Kandl TJ, Thakar SD, Thuro BA,
Busaidy NL, Cabanillas M, Jimenez C, Dadu R, Graham PH, Debnam JM
and Esmaeli B: Extraocular muscle enlargement and thyroid eye
disease-like orbital inflammation associated with immune checkpoint
inhibitor therapy in cancer patients. Ophthalmic Plast Reconstr
Surg. 35:50–52. 2019. View Article : Google Scholar
|
|
114
|
Gauci ML, Laly P, Vidal-Trecan T,
Baroudjian B, Gottlieb J, Madjlessi-Ezra N, Da Meda L,
Madelaine-Chambrin I, Bagot M, Basset-Seguin N, et al: Autoimmune
diabetes induced by PD-1 inhibitor-retrospective analysis and
pathogenesis: A case report and literature review. Cancer Immunol
Immunother. 66:1399–1410. 2017. View Article : Google Scholar
|
|
115
|
Okamoto M, Okamoto M, Gotoh K, Masaki T,
Ozeki Y, Ando H, Anai M, Sato A, Yoshida Y, Ueda S, et al:
Fulminant type 1 diabetes mellitus with anti-programmed cell
death-1 therapy. J Diabetes Investig. 7:915–918. 2016. View Article : Google Scholar
|
|
116
|
Rossi E, Sgambato A, De Chiara G, Casaluce
F, Losanno T, Sacco PC, Santabarbara G and Gridelli C:
Endocrinopathies induced by immune-checkpoint inhibitors in
advanced non-small cell lung cancer. Expert Rev Clin Pharmacol.
9:419–428. 2016. View Article : Google Scholar
|
|
117
|
Kim KH, Sim WY and Lew BL:
Nivolumab-induced alopecia areata: A case report and literature
review. Ann Dermatol. 33:284–288. 2021. View Article : Google Scholar
|
|
118
|
Navarro-Fernandez I, Gonzalez-Vela C,
Gomez-Fernandez C, Duran-Vian C, Reguero L and Gonzalez-Lopez M:
Vitiligo-like depigmentation in a patient undergoing treatment with
nivolumab for advanced renal-cell carcinoma. Acta Dermatovenerol
Croat. 291:54–55. 2021.
|
|
119
|
Gracia-Cazana T, Padgett E,
Hernandez-Garcia A and Sanchez-Salas MP: Vitiligo-like lesions
located over In-transit metastases of malignant melanoma as a
clinical marker of complete response to pembrolizumab. Dermatol
Online J. 25:13030/qt8d3818j52019. View Article : Google Scholar
|
|
120
|
Cardis MA, Jiang H, Strauss J, Gulley JL
and Brownell I: Diffuse lichen planus-like keratoses and clinical
pseudo-progression associated with avelumab treatment for Merkel
cell carcinoma, a case report. BMC Cancer. 19:5392019. View Article : Google Scholar
|
|
121
|
Rambhia PH, Honda K and Arbesman J:
Nivolumab induced inflammation of seborrheic keratoses: A novel
cutaneous manifestation in a metastatic melanoma patient. Melanoma
Res. 28:475–477. 2018. View Article : Google Scholar
|
|
122
|
Lopez AT, Khanna T, Antonov N,
Audrey-Bayan C and Geskin L: A review of bullous pemphigoid
associated with PD-1 and PD-L1 inhibitors. Int J Dermatol.
57:664–669. 2018. View Article : Google Scholar
|
|
123
|
Obara K, Masuzawa M and Amoh Y: Oral
lichenoid reaction showing multiple ulcers associated with
anti-programmed death cell receptor-1 treatment: A report of two
cases and published work review. J Dermatol. 45:587–591. 2018.
View Article : Google Scholar
|
|
124
|
Seethapathy H, Zhao S, Strohbehn IA, Lee
M, Chute DF, Bates H, Molina GE, Zubiri L, Gupta S, Motwani S, et
al: Incidence and clinical features of immune-related acute kidney
injury in patients receiving programmed cell death ligand-1
inhibitors. Kidney Int Rep. 5:1700–1705. 2020. View Article : Google Scholar
|
|
125
|
Bickel A, Koneth I, Enzler-Tschudy A,
Neuweiler J, Flatz L and Fruh M: Pembrolizumab-associated minimal
change disease in a patient with malignant pleural mesothelioma.
BMC Cancer. 16:6562016. View Article : Google Scholar
|
|
126
|
Boegeholz J, Brueggen CS, Pauli C,
Dimitriou F, Haralambieva E, Dummer R, Manz MG and Widmer CC:
Challenges in diagnosis and management of neutropenia upon exposure
to immune-checkpoint inhibitors: Meta-analysis of a rare
immune-related adverse side effect. BMC Cancer. 20:3002020.
View Article : Google Scholar
|
|
127
|
Wang W, Lam WC and Chen L: Recurrent grade
4 panuveitis with serous retinal detachment related to nivolumab
treatment in a patient with metastatic renal cell carcinoma. Cancer
Immunol Immunother. 68:85–95. 2019. View Article : Google Scholar
|
|
128
|
Yatim N, Mateus C and Charles P:
Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic
melanoma in a patient undergoing complete remission. Rev Med
Interne. 39:130–133. 2018. View Article : Google Scholar
|
|
129
|
Zheng Y, Meng X, Zweigenbaum P, Chen L and
Xia J: Hybrid phenotype mining method for investigating off-target
protein and underlying side effects of anti-tumor immunotherapy.
BMC Med Inform Decis Mak. 20(Suppl 3): S1332020. View Article : Google Scholar
|
|
130
|
Gauci ML, Baroudjian B, Laly P, Madelaine
I, Da Meda L, Vercellino L, Bagot M, Liote F, Pages C and Lebbe C:
Remitting seronegative symmetrical synovitis with pitting edema
(RS3PE) syndrome induced by nivolumab. Semin Arthritis Rheum.
47:281–287. 2017. View Article : Google Scholar
|
|
131
|
Uemura M, Fa'ak F, Haymaker C, McQuail N,
Sirmans E, Hudgens CW, Barbara L, Bernatchez C, Curry JL, Hwu P, et
al: Erratum to: A case report of Grover's disease from
immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but
not PD-1. J Immunother Cancer. 5:72017. View Article : Google Scholar
|
